<DOC>
	<DOC>NCT02572349</DOC>
	<brief_summary>The objectives of the study are to assess the safety and tolerability of a range of single doses of IW-1701 when administered as oral capsules to healthy subjects, to determine the pharmacokinetic profile and pharmacodynamics effects of a range of single doses of IW-1701 when administered as oral capsules to healthy subjects.</brief_summary>
	<brief_title>Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion: Between 18 and 60 years old at the Screening Visit; Women of childbearing potential must have a negative pregnancy test and must agree to use doublebarrier contraception; BMI &gt; 18.5 and &lt; 32.0 kg/m2 at the Screening Visit; In overall good health with no clinically significant laboratory, ECG, or physical exam findings; Other inclusion criteria per protocol. Exclusion: History of any clinicallysignificant medical condition; Other exclusion criteria per protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Healthy Subjects</keyword>
</DOC>